Ember Therapeutics is a product-focused company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease. Today's growing epidemic of obesity and Type 2 diabetes, coupled with a critical need for innovation in the industry's metabolic disease treatment pipeline, underscores the need for novel, peripherally-acting treatments with improved safety profiles.
Ember's unique approach builds upon recent research breakthroughs into the mechanism of brown fat activity to develop a pipeline of proprietary large and small molecules designed to amplify the body's innate ability to efficiently burn fuels like glucose. Ember's expertise is also driving the development of the next generation of highly selective insulin sensitizers that have robust anti-diabetic effects, but lack the serious side effects of currently approved insulin sensitizers. Ember has exclusively licensed key technology and intellectual property generated by its scientific founders and advisors.
Ember Therapeutics is a private company launched in 2011 by renowned scientific founders, an experienced leadership team and Third Rock Ventures.